Sign up for our daily briefing
Make your busy days simpler with Axios AM/PM. Catch up on what's new and why it matters in just 5 minutes.
Stay on top of the latest market trends
Subscribe to Axios Markets for the latest market trends and economic insights. Sign up for free.
Sports news worthy of your time
Binge on the stats and stories that drive the sports world with Axios Sports. Sign up for free.
Tech news worthy of your time
Get our smart take on technology from the Valley and D.C. with Axios Login. Sign up for free.
Get the inside stories
Get an insider's guide to the new White House with Axios Sneak Peek. Sign up for free.
Catch up on coronavirus stories and special reports, curated by Mike Allen everyday
Catch up on coronavirus stories and special reports, curated by Mike Allen everyday
Want a daily digest of the top Denver news?
Get a daily digest of the most important stories affecting your hometown with Axios Denver
Want a daily digest of the top Des Moines news?
Get a daily digest of the most important stories affecting your hometown with Axios Des Moines
Want a daily digest of the top Twin Cities news?
Get a daily digest of the most important stories affecting your hometown with Axios Twin Cities
Want a daily digest of the top Tampa Bay news?
Get a daily digest of the most important stories affecting your hometown with Axios Tampa Bay
Want a daily digest of the top Charlotte news?
Get a daily digest of the most important stories affecting your hometown with Axios Charlotte
Craig Ruttle / AP
Confirming yesterday's buzz, PhRMA, the pharmaceutical industry's primary lobbying group, announced changes to its membership structure today that include stricter membership requirements and the elimination of its "associate" category. As a result, 22 companies lost their membership or associate membership status. The new requirements, based on a three-year average:
- At least $200 million per year spent on research
- Research expenditures equal to at least 10% of global sales
Why it matters: As we said yesterday, this is PhRMA's way of trying to get rid of smaller companies that engage in the controversial practice of buying older drugs and jacking up the prices. Read on to see who's out.
Former members, per PhRMA:
- AMAG Pharmaceuticals, Inc.
- Horizon Pharma plc
- Jazz Pharmaceuticals plc
- Leadiant Biosciences
- Mallinckrodt Pharmaceuticals
- Orexigen Therapeutics, Inc.
- The Medicines Company
Former associate members, per PhRMA:
- ACADIA Pharmaceuticals Inc.
- Aerie Pharmaceuticals, Inc.
- Avanir Pharmaceuticals, Inc.
- BioMarin Pharmaceutical Inc.
- CSL Behring, LLC
- Esperion Therapeutics, Inc.
- Ferring Pharmaceuticals Inc.
- Grifols USA, LLC
- Ipsen Biopharmaceuticals, Inc.
- Marathon Pharmaceuticals, LLC
- Shionogi Inc.
- Sucampo Pharmaceuticals, Inc.
- Theravance Biopharma
- Vifor Pharma
- VIVUS, Inc.